Bristol-Myers Squibb and Emory University have formed a strategic partnership to conduct clinical trials involving BMS' investigational compounds. Investigators from Emory and affiliated institutions will conduct Phase II, III and pediatric trials in the metropolitan Atlanta area to support the ongoing development of investigational medicines from across BMS' portfolio, particularly in oncology, metabolics, hepatitis C and immunoscience.

This agreement builds on recent experiences between the two organizations in conducting clinical trials in organ transplantation and cancer. In the first studies under the new agreement, researchers from the Winship Cancer Institute of Emory University will work with BMS scientists on multiple clinical trial programs in oncology.

“This partnership is aligned with BMS' strategy, which embraces the opportunity to selectively integrate the expertise of other organizations with our own to best meet the treatment needs of patients,” said Brian Daniels, senior vice president, Global Development & Medical Affairs, BMS. “Our expectation is that the shared commitment of providing innovative solutions for patients, the world-class talent at both organizations and the clinical trial expertise at Emory, will result in important advancements in the understanding of BMS compounds and their potential for treating patients with devastating diseases, such as cancer.”